178 related articles for article (PubMed ID: 25371577)
21. Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats.
Van Etten EW; Stearne-Cullen LE; ten Kate M; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2000 Mar; 44(3):540-5. PubMed ID: 10681315
[TBL] [Abstract][Full Text] [Related]
22. Preclinical Evaluation of Recombinant Microbial Glycoside Hydrolases in the Prevention of Experimental Invasive Aspergillosis.
Ostapska H; Raju D; Lehoux M; Lacdao I; Gilbert S; Sivarajah P; Bamford NC; Baker P; Nguyen TTM; Zacharias CA; Gravelat FN; Howell PL; Sheppard DC
mBio; 2021 Oct; 12(5):e0244621. PubMed ID: 34579578
[TBL] [Abstract][Full Text] [Related]
23. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.
Warn PA; Sharp A; Morrissey G; Denning DW
Int J Antimicrob Agents; 2010 Feb; 35(2):146-51. PubMed ID: 20015618
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
[TBL] [Abstract][Full Text] [Related]
25.
Siopi M; Mouton JW; Pournaras S; Meletiadis J
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962332
[No Abstract] [Full Text] [Related]
26. Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study.
Hoenigl M; Prattes J; Neumeister P; Wölfler A; Krause R
Mycoses; 2018 Mar; 61(3):201-205. PubMed ID: 29112326
[TBL] [Abstract][Full Text] [Related]
27. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S
Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443
[TBL] [Abstract][Full Text] [Related]
28. Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection.
Barchiesi F; Santinelli A; Biscotti T; Greganti G; Giannini D; Manso E
J Antimicrob Chemother; 2016 Aug; 71(8):2230-3. PubMed ID: 27231274
[TBL] [Abstract][Full Text] [Related]
29. Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis.
Ruijgrok EJ; Fens MH; Bakker-Woudenberg IA; van Etten EW; Vulto AG
Antimicrob Agents Chemother; 2006 May; 50(5):1852-4. PubMed ID: 16641459
[TBL] [Abstract][Full Text] [Related]
30. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.
Hope WW; Petraitis V; Petraitiene R; Aghamolla T; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2010 Nov; 54(11):4879-86. PubMed ID: 20713673
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
32. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Schaufele RL; Francesconi A; Bacher J; Avila NA; Walsh TJ
Antimicrob Agents Chemother; 2002 Jan; 46(1):12-23. PubMed ID: 11751105
[TBL] [Abstract][Full Text] [Related]
33. The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis.
Ibrahim AS; Gebremariam T; French SW; Edwards JE; Spellberg B
J Antimicrob Chemother; 2010 Feb; 65(2):289-92. PubMed ID: 19942619
[TBL] [Abstract][Full Text] [Related]
34. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
Verweij PE; Oakley KL; Morrissey J; Morrissey G; Denning DW
Antimicrob Agents Chemother; 1998 Apr; 42(4):873-8. PubMed ID: 9559799
[TBL] [Abstract][Full Text] [Related]
36. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice.
Wallace TL; Paetznick V; Cossum PA; Lopez-Berestein G; Rex JH; Anaissie E
Antimicrob Agents Chemother; 1997 Oct; 41(10):2238-43. PubMed ID: 9333054
[TBL] [Abstract][Full Text] [Related]
37. Host biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response.
Krel M; Petraitis V; Petraitiene R; Jain MR; Zhao Y; Li H; Walsh TJ; Perlin DS
Antimicrob Agents Chemother; 2014 Jun; 58(6):3373-8. PubMed ID: 24687510
[TBL] [Abstract][Full Text] [Related]
38. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Prince RA; Chi J; Kontoyiannis DP
Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846
[TBL] [Abstract][Full Text] [Related]
39. Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatus.
Stergiopoulou T; Meletiadis J; Sein T; Papaioannidou P; Walsh TJ; Roilides E
Antimicrob Agents Chemother; 2011 Dec; 55(12):5923-9. PubMed ID: 21911564
[TBL] [Abstract][Full Text] [Related]
40. Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™.
Italia JL; Sharp A; Carter KC; Warn P; Kumar MN
PLoS One; 2011; 6(10):e25744. PubMed ID: 21998690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
